Data from: Human parainfluenza virus 3 fusion protein cleavage: A key determinant of infection and spread
Data files
May 09, 2026 version files 11.96 MB
-
All_Data.xlsx
31.63 KB
-
Figure_1A_RAW.pdf
3.70 MB
-
Figure_1B_RAW.pdf
2.05 MB
-
Figure_3A_RAW_Blot.pdf
2.33 MB
-
FIgure_3E_RAW_blot.pdf
2.60 MB
-
Figure_5A_RAW_Blot.pdf
803.92 KB
-
Figure_S1.pdf
441.30 KB
-
README.md
6.54 KB
Abstract
Human parainfluenza virus 3 (HPIV3) entry into target cells depends on a viral fusion complex composed of hemagglutinin-neuraminidase (HN) and fusion protein (F). In addition to attachment, HN activates F to mediate membrane fusion, while its neuraminidase activity promotes viral release. This creates a biological paradox: virions must repeatedly engage sialic acid-rich substrates in the airway without prematurely triggering F, until they reach the target cell sialic acid receptor. Unlike the F proteins of laboratory strains that are cleaved intracellularly by furin to process F from its pro-protein to the active form that is essential for fusion, the F proteins of HPIV3 field strains lack a furin cleavage site and undergo partial cleavage mediated by extracellular serine proteases. We show that virions isolated directly from infected humans contain both cleaved and uncleaved F. In viral migration assays, reducing the proportion of cleaved F on virions increases the distance virions travel before infecting a cell. Even virions bearing only uncleaved F upon egress from infected cells can establish infection in vivo. These findings support a model in which uncleaved F on viral surfaces permits virions to engage and disengage sialylated substrates without undergoing premature fusion protein triggering, allowing virions to traverse the airway. Cleavage of F at the target cell then licenses membrane fusion, ensuring that virions initiate infection at the correct site. HPIV3 exploits host protease environments to produce virions with heterogeneity in F cleavage, equipped to either establish local infection or spread to distant target cells.
Dataset DOI: 10.5061/dryad.xd2547dwk
Description of the data and file structure
These data were collected in support of the research article, "Human parainfluenza virus 3 fusion protein cleavage: a key determinant of infection and spread".
Files and variables
File: Figure_1A_RAW.pdf
Description: Raw PDF file of HPIV3 F E108 and HPIV3 F K108 from HAE, Vero and Calu-3 cells resolved by reducing SDS-PAGE and immunoblotted with an anti-HPIV3 F HRC antibody.
File: Figure_1B_RAW.pdf
Description: Raw PDF file of HPIV3 directly from HPIV3-infected humans without passage was lysed and immunoprecipitated with anti-HPIV3 HN antibodies, resolved by reducing SDS-PAGE, and immunoblotted with an anti-HPIV3 F antibody.
File: Figure_S1.pdf
Description: Raw PDF file of HPIV3 directly from HPIV3-infected humans without passage was lysed and immunoprecipitated with anti-HPIV3 HN antibodies, resolved by reducing SDS-PAGE, and immunoblotted with an anti-HPIV3 F antibody.
File: FIgure_3E_RAW_blot.pdf
Description: Raw PDF file of HPIV3 F E108 eGFP and HPIV3 F K108 mCherry grown in Calu-3 in the presence of vehicle, 10µM aprotinin, or 0.1µg/ml TPCK treated trypsin, resolved by reducing SDS-PAGE and immunoblotted with anti-HPIV3 F antibody.
File: Figure_3A_RAW_Blot.pdf
Description: Raw PDF file of HPIV3 F E108 mCherry grown in Calu-3 cells and HPIV3 F K108 eGFP grown in HAE resolved by reducing SDS-PAGE and immunoblotted with anti-HPIV3 F antibody.
File: Figure_5A_RAW_Blot.pdf
Description: Raw PDF file of HPIV3 F E108 and HPIV3 F1-F2 E108 from Vero cells resolved by reducing SDS-PAGE and immunoblotted with an anti-HPIV3 F antibody.
File: All_Data.xlsx
Description: All raw Data included in the manuscript body figures. They are described in the legends below.
FIG 1 - In HPIV3 collected directly from infected human subjects, approximately half of the fusion proteins are cleaved. (A) HPIV3 F E108 and HPIV3 F K108 from HAE, Vero and Calu-3 cells resolved by reducing SDS-PAGE and immunoblotted with an anti-HPIV3 F HRC antibody. (B) HPIV3 directly from HPIV3-infected humans without passage was lysed and immunoprecipitated with anti-HPIV3 HN antibodies, resolved by reducing SDS-PAGE, and immunoblotted with an anti-HPIV3 F antibody. (C) Densitometry analysis of the HPIV3 F0 (uncleaved) and F1 (cleaved) band intensities.
FIG 2 - Cleaved F triggers faster than uncleaved F in the presence of receptor-bound HN.
Activation of (A) uncleaved F or (B) cleaved F by receptor-bound HN after 0 to 60 minutes at 37 °C. F triggering measured by the percent of red blood cells (RBCs) released, reversibly bound, irreversibly bound, or fused with the HN-F-expressing cells. (C) Summary of percent RBCs fused or irreversibly bound. *P ≤ 0.05, ** P ≤ 0.01 by two-way ANOVA and Sidak’s post hoc test. Data are means ± SEM from at least three separate experiments.
FIG 3 - HPIV3 spread distance is inversely proportional to F cleavage.
(A) HPIV3 F E108 mCherry grown in Calu-3 cells and HPIV3 F K108 eGFP grown in HAE resolved by reducing SDS-PAGE and immunoblotted with anti-HPIV3 F antibody. The proportion of uncleaved F0 was determined by densitometry. (B, C) Distance HPIV3 F E108 mCherry and HPIV3 F K108 eGFP traveled from site of inoculation following (B) single entry or (C) five days of multicycle replication. Proportion of HPIV3 F cleaved. * P ≤ 0.05, ***\ P ≤ 0.001 by paired t-test. (D) Distance HPIV3 F E108 eGFP and HPIV3 F K108 mCherry traveled from site of inoculation following 5 days of multicycle replication in the presence of 0, 0.1, 1, or 10µM aprotinin. ** P ≤ 0.01, *** P ≤ 0.001 by two-way ANOVA and Holm-Sidak’s post hoc test. (E) HPIV3 F E108 eGFP and HPIV3 F K108 mCherry grown in Calu-3 in the presence of vehicle, 10µM aprotinin, or 0.1µg/ml TPCK treated trypsin, resolved by reducing SDS-PAGE and immunoblotted with anti-HPIV3 F antibody. The proportion of uncleaved F0 present in virus solutions was determined with densitometry. (F) Distance HPIV3 F E108 eGFP and HPIV3 F K108 mCherry traveled from site of inoculation following 5 days of multicycle replication in the presence of vehicle, 10µM aprotinin, or 0.1µg/ml TPCK treated trypsin. * P ≤ 0.05, ** P ≤ 0.01 by two-way ANOVA and Holm-Sidak’s post hoc test. Values are means and +/-SEM from at least three biological replicates.
FIG 4 - HPIV3 F E108 mediates cell-cell fusion when paired with an HN that continually engages receptor.
Percent fusion mediated by influenza HA, HPIV3 HN, HPIV3 HN D216R expressed with no F (black), no F targeting cells expressing TMPRSS2 in trans (grey), F E108 (red), F E108 targeting cells expressing TMPRSS2 in trans (green), F K108 (blue), F K108 targeting cells expressing TMPRSS2 in trans (purple). (A) Fusion activity measured with β-galactosidase complementation assay. (D) Fusion activity measured with VP64-GFP1-10 with dCas9-GFP11 complementation assay. (B, E) Schematic of complementation assays. (C, F) Representative images 16 hours after overlaying target cells on viral surrogate cells. *** P ≤ 0.001, **** P ≤ 0.0001 by one-way ANOVA and Dunnett’s post hoc test. Data are means ± SEM from at least three separate experiments.
FIG 5 - HPIV3 bearing only F0 can infect cotton rats
Cotton rats were intranasally inoculated with 1.5x105 PFU of HPIV3 F E108 alone (F0 E108) or HPIV3 F E108 treated with TPCK-treated trypsin (F1-F2 E108). 5 animals in each infected group; 3 uninfected animals. Nasal and lung tissue homogenates were collected 3 or 5 days post infection. (A) HPIV3 F E108 and HPIV3 F1-F2 E108 from Vero cells resolved by reducing SDS-PAGE and immunoblotted with an anti-HPIV3 F antibody. (B-C) HPIV3 RNA levels in nasal (B) or lung (C) homogenates detected with RT-qPCR. Significant HPIV3 gene expression was detected in all HPIV3 inoculated animals relative to no infection controls with P ≤ 0.0001 determined by one-way ANOVA and Dunnett’s post hoc test. Data are means ± SEM from at least three separate experiments.
Code/software
Any verison of ImageJ (NIH), Preview (Apple), or Acrobat (Adobe) can be used to view the PDFs.
Any version of Microsoft Excel can be used to view the "All_Data" Excel sheet.
